Changzhou Kaiqiao Biotechnology Co.,Ltd

Telephone:

+86-180-38176818

Pirfenidone Pharmaceutical Intermediates
Pirfenidone Pharmaceutical Intermediates

Pirfenidone Pharmaceutical Intermediates

Contact : Mr.Thyen-------------------------------- Email us at zhangyinglong@ycphar.com Whatsapp : +86 180 3817 6818

Send Inquiry

  • Product Details

Pirfenidone


Contact : Mr.Thyen

Email us at zhangyinglong@ycphar.com

Whatsapp : +86 180 3817 6818


What is pirfenidone?

Pirfenidone is used to treat a lung disease called idiopathic pulmonary fibrosis (IPF). IPF causes scar tissue to form deep within your lungs. The scar tissue thickens and becomes stiff or thick over time, which can make it harder for your lungs to work. Decreased lung function can make it hard for you to breathe. Other medical problems can occur when your brain, heart, and other organs do not get enough oxygen.

The cause of IPF is often unknown, but this condition is a progressive disease that can be fatal. Pirfenidone is not a cure for IPF, but this medicine may slow the progress of this disease.

Pirfenidone may also be used for purposes not listed in this medication guide.

 

Quick Detail

Product name

Pirfenidone

Other name

5-Methyl-N-phenyl-2-1H-pyridone

CAS

53179-13-8

MF

185.22

MW;

483.95

Molecular structure

img10615.JPG

Assay

99%

Appearance

White crystal powder

Usage

Treatment of Pulmonary Fibrosis


Description

In the Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis (ASCEND) study, a randomized, double-blind, placebo-controlled trial, we aimed to confirm the effect of pirfenidone on disease progression in patients with idiopathic pulmonary fibrosis. Our design modifications with respect to the CAPACITY trial included the implementation of centralized procedures for diagnosis, spirometry, ,

Pirfenidone is an oral antifibrotic therapy that has been evaluated for the treatment of idiopathic pulmonary fibrosis in three phase 3, randomized, controlled trials. One of these trials was conducted in Japan and involved 275 patients. It was followed by two multinational studies, Clinical Studies Assessing Pirfenidone in Idiopathic Pulmonary Fibrosis: Research of Efficacy and Safety Outcomes, that were conducted in the United States, Europe, and Australia and involved 779 patients.7,8 In the Japanese trial, pirfenidone reduced the decline in vital capacity at week 52 and improved progression-free survival. In the multinational trials, the primary end point of change from baseline to week 72 in the percentage of the predicted forced vital capacitywas met in study 004 but not in study 006, prompting U.S. regulatory authorities to request an additional trial to support the approval of pirfenidone.

 

Applications

Pirfenidone has proven antifibrotic and anti-inflammatory properties in various in vitro systems and animal models of pulmonary fibrosis, although its precise mechanism of action remains unclear. It attenuates fibroblast proliferation, production of fibrosis-associated proteins and cytokines, and the increased biosynthesis and accumulation of extracellular matrix in response to cytokines such as transforming growth factor. It is also shown to slow tumor cell proliferation by inhibiting fibroblast growth factor, epidermal growth factor and platelet-derived growth factor.

Idiopathic pulmonary fibrosis is characterized by radiographically evident interstitial infiltrates predominantly affecting the lung bases and by progressive dyspnea and worsening of pulmonary function. No therapy has been clearly shown to prolong survival. The current strict definition of idiopathic pulmonary fibrosis provides a new focus for basic and clinical research that will improve insight into the pathogenesis of this disorder and stimulate the development of novel therapies.

 

COA

Product

Pirfenidone

Batch No.

150301

Man.date

Mar.30,2015

Expiry date

Mar.29,2018

Testing date

Mar.30,2015

Report date

Mar.31,2015

Quantity

30kg

Quality standard

Enterprise Standard

Items

Specifications

Results

Appearance

A little yellow to white powder

Pass

Identification

IR As stipulation

Pass

Loss on drying

No more than 1.0%

0.22%

Heavy metal

No more than 20ppm

Pass

Sulphated ash

No more than 0.2%

0.10%

Any impurity

No more than 0.5%

0.13%

Total impurity

No more than 1.0%

0.30%

Assay

99.0%~101.0%

99.70%

Conclusion

Qualified


How should I take pirfenidone?

(1)Your doctor will perform blood tests to make sure you do not have conditions that would prevent you from safely using pirfenidone.

(2)Follow all directions on your prescription label. Do not use this medicine in larger or smaller amounts or for longer than

recommended.

(3)Pirfenidone should be taken with food to help decrease nausea or dizziness.

(4)Pirfenidone is usually taken 3 times per day. Your dose needs will change over the first 15 days of your treatment.

For the first week, you will take only 1 capsule at a time.

During the second week, you will take 2 capsules at a time.

From the third week on, you will take 3 capsules at a time.

You must follow this 2-week "dose escalation" schedule when you start taking pirfenidone, or if you start taking the medicine again after not taking it for 14 days or longer. Follow your doctor's dosing instructions very carefully.

 

Function

1. Idiopathic pulmonary fibrosis degeneration

2. Liver Fibrosis

3. Renal fibrosis disease

4. Multiple Sclerosis

5. Myocardial fibrosis

6. Neoplastic diseases: neurofibroma, leiomyoma, and malignant gliomas.

7. Prevention of fibrosis after the organ transplant.

8. Rheumatoid arthritis.

 

More products we supply

CAS#

Name

Mol. F.

93609-84-8

Carmoterol Intermediate

C18H15NO3

312753-53-0

Indacaterol Intermediate

C13H20ClN

143612-79-7

Vilazodone Intermediate

C13H13ClN2

167933-07-5

Flibanserin

C20H21F3N4O

147359-76-0

Flibanserin HCl

C20H22ClF3N4O

38183-03-8

7,8-Dihydroxyflavone

C15H10O4

1205548-00-0

4'-Dimethylamino 7,8-Dihydroxyflavone

C17H15NO4

6358-53-8

Citrus Red 2

C18H16N2O3

615-16-7

2-Hydroxybenzimidazole

C7H6N2O

3601-89-6

1-Chloro-3,5-di-O-toluoyl-2-deoxy-D-ribofuranose

C21H21ClO5

394-28-5

2-Bromo-5-fluorobenzoic acid

C7H4BrFO2

1345680-97-8

P1301

C12H26N2O4

20511-12-0

2-Amino-5-iodopyridine

C5H5IN2

614750-84-4

LH0190

C6H4IN3

5803-30-5

2,5-Dimethoxypropiophenone

C11H14O3

4353-06-4

2-Nonyldioxolane

C12H24O2

35943-35-2

Triciribine

C13H16N6O4


Competitive Advantage

1. Our company is a professional production leading factory in China in pharmaceutical area of many years.

Delivery areas of our products: US, UK, Canada, Australia, Brazil, Russia, Portugal, Latvia, Switzerland, Iceland, Ukraine, Germany, France, Netherlands, Belgium, Peru, Sweden, New Zealand, the Czech Republic, Lithuania, Ireland, Tunisia, Mexico, Greece, Puerto Rico, Thailand, Israel and so on.

Payment method: T/T, Western union, Moneygram, bitcoin etc.

2. Discreet package. The packing suits you best would be choosen to cross customs safely. Or if you have your own ideal way, it could be also take into consideration.

3. Top quality. High quality guarenteed, once any problem is found, the package would be reshipped for you.

4. Security Shipping: Shipping by express (FedEx, UPS, DHL, EMS), by air. The most professional forwarder would be recommanded for you.

5. We have stock, so we can delivery quickly at the very day when receive the payment.

6. Warm after-sale service for you 24/7. Any of your question would be solved for the first as soon as possible.

7. A discount would be given when you make a large order.

Hot Tags: pirfenidone pharmaceutical intermediates, China, suppliers, manufacturers, wholesale, buy, price
Related Products
  • Feedback